TC
SGYP

Trilogy Capital’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Trilogy Capital’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed – – 643
2018
Q3 		$0 Hold
200
– – ﹤0.01% 678
2018
Q2 		$0 Hold
200
– – ﹤0.01% 646
2018
Q1 		$0 Buy
+200
New +$422 ﹤0.01% 522

Other funds holding SGYP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Trilogy Capital's SGYP Position: Q4 2018 in Review

Trilogy Capital sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2018, closing a stake of 200 shares.

Trilogy Capital first reported a position in SGYP in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 89 funds tracked by Wall St. Rank hold SGYP as of Q4 2018.

  • Trilogy Capital reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2018 after selling out during the quarter.
  • Trilogy Capital sold 200 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2018.
  • Trilogy Capital first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2018 and held it in 3 quarters.
  • Trilogy Capital's Synergy Pharmaceuticals, Inc Common Stock position peaked at $0 in Q3 2018.
  • 89 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.